Merck + Co., Inc.

Dennis C Dean

David G Melillo

David A Claremon

Nigel J Liverton

Ravi P Nargund

Bruce D Dorsey

Alan John Nadin

John W Butcher

Jules A Shafer

Roy G Smith

Leonardus H Van Der Ploeg

Thomas M Connolly

Yueming Li

Joseph George Neduvelil

Ming-Tain Lai

Kenneth S Koblan

Mohinder Sardana

Sheng-Shung Pong

James M Schaeffer

Stephen J Gardell

Jerzy Karczewski

Matthew J Kostura

The present invention is directed to the radioligand compound, [S]-radiolabeled (+)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydoxyspiro[2H-1-benzopyran-2,4&#x2032;-piperidin]-6-yl]methanesulfonamide. Also within the scope of this invention is a method for identifying compounds that bind to the Ichannel, and may have antiarrhythmic activity.

Radioligand and binding assay

The present invention is directed to compounds and pharmaceutical compositions comprising the compounds which are inhibitors of the enzyme gamma secretase and which are useful in the treatment or prevention of diseases in which the beta-amyloid peptide is involved, such as Alzheimer's disease.

Investigational compounds

The present invention is directed to �.sup.35 S!-N-�1(R)-�(1,2-dihydro-1-methanesulfonylspiro�3H-indole-3,4'-piperidin!- 1'-yl)carbonyl!-2-(phenylmethyloxy)ethyl!-2-amino-2-methylpropanamide, and pharmaceutically acceptable salts thereof. This �.sup.35 S! radioligand is useful in identifying and characterizing cellular receptors which play a role in the activity of growth hormone secretatogogues. In addition, this �.sup.35 S! radioligand is useful in assays which test compounds for growth hormone secretagogue activity.

Radiolabeled growth hormone secretagogue

Growing community of inventors

Chatham, NJ, United States of America

Dennis C Dean